Get the Stockscreener App
40.50
0.75%
0.30
After Hours:
40.06
-0.44
-1.09%
Harrow Inc stock is traded at $40.50, with a volume of 442.04K.
It is up +0.75% in the last 24 hours and up +14.70% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$40.20
Open:
$40.41
24h Volume:
442.04K
Relative Volume:
0.63
Market Cap:
$1.51B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-247.71
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
+0.05%
1M Performance:
+14.70%
6M Performance:
+14.34%
1Y Performance:
+63.77%
1-Day Range:
$40.08
$41.20
1-Week Range:
$38.71
$41.66
52-Week Range:
$21.12
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
40.50 | 1.50B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
MSN Money - MSN
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Record 2025 Results And Boosted Investment Could Be A Game Changer For Harrow (HROW) - Sahm
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Insider Monkey
Harrow announces $50M add-on senior notes offering - MSN
Harrow Inc (HROW) Stock Up 4.2% and Still Undervalued -- GF Scor - GuruFocus
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 - GlobeNewswire
Harrow posts Q1 stockholder letter May 11, then webcasts call May 12 - Stock Titan
Executive pay and board structure at Harrow (NASDAQ: HROW) 2026 meeting - Stock Titan
Harrow | DEFA14A: Others - Moomoo
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Harrow (HROW) Stock: Mistakes to Avoid (Underperforming) 2026-04-20Delta Trends - Xã Thanh Hà
Harrow: Now Is The Buy Time (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (NASDAQ:HROW) Presents a Compelling Case for Affordable Growth - ChartMill
HROW Reiterated by BTIG -- Price Target Maintained at $63.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and BioCryst (BCRX) - The Globe and Mail
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Harrow Announces the Issuance of J-Code for IOPIDINE® 1% - Sahm
HROW Forecast, Price Target & Analyst Ratings | HARROW INC (NASDAQ:HROW) - ChartMill
Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength - Eastern Progress
Harrow Inc (HROW) Stock Up 4.8% and Still Undervalued -- GF Scor - GuruFocus
Harrow Secures Permanent J-Code for Iopidine 1% (HROW) - GuruFocus
Harrow (FRA:3IP) Shiller PE Ratio : (As of Apr. 17, 2026) - GuruFocus
Harrow Inc (FRA:3IP) Stock Price & 30 Year Financial Data - GuruFocus
Q3 2025 Harrow Inc Earnings Call Transcript - GuruFocus
Harrow Inc (FRA:3IP) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Does Harrow’s New LogiCare3PL Partnership (HROW) Reveal an Emerging Edge in Eyecare Distribution? - simplywall.st
Harrow: Now Is The Buy Time - Seeking Alpha
Harrow (HROW) Partners with LogiCare3PL for Distribution Services - GuruFocus
Harrow Selects LogiCare3PL as U.S. Distribution Partner for Ophthalmic Portfolio - citybiz
Harrow Taps LogiCare3PL as Distribution Partner - marketscreener.com
LogiCare3PL Selected as Distribution Partner by Harrow - ChartMill
Harrow: Probably A Short-Term Market Overreaction (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (NASDAQ:HROW) Presents a Growth and Breakout Opportunity - ChartMill
Harrow shifts U.S. eye drug distribution to LogiCare3PL in 4 weeks - Stock Titan
Assessing Harrow (HROW) Valuation After US$8.1 Million In Recent Insider Stock Sales - Yahoo Finance
Harrow Inc (HROW) Stock Up 3.3% and Still Undervalued -- GF Scor - GuruFocus
Harrow Inc (HROW) Shares Fall 3.6% -- What GF Score of 86 Tells Investors - GuruFocus
How Harrow Health Inc. 8.625% Senior Notes Due 2026 (HROWL) Affects Rotational Strategy Timing - Stock Traders Daily
3IP: Static price chart | Harrow, Inc. | US4158581094 - marketscreener.com
BTIG to Host Virtual Meeting Focused on HROW This April - GuruFocus
HROW Virtual Meeting Scheduled for April 14 - GuruFocus
Working capital per share of Harrow, Inc. – FWB:3IP - TradingView
Cash per share of Harrow, Inc. – FWB:3IP - TradingView
Long term debt to total assets ratio of Harrow, Inc. – FWB:3IP - TradingView
BTIG Maintains Buy on Harrow Health, Inc. (HROW) March 2026 - Meyka
Buy Signal: Can Harrow Inc maintain sales growth2026 Historical Comparison & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):